FDA advisory panel endorsed Grail's multi-cancer blood test in a split vote
The committee voted 7-2 that Galleri's benefits outweigh its risks, though members split 6-4 on the question of effectiveness
We haven't written up this one. Quartz has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.